Alimera Sciences Recommandation moyenne
Quel est le Recommandation moyenne de Alimera Sciences?
Le Recommandation moyenne de Alimera Sciences Inc. est 1.00
Quelle est la définition de Recommandation moyenne?
La moyenne recommandée est la moyenne des évaluations des actions par les analystes allant de 1,0 (achat fort) à 5,0 (vente forte).
Mean of recommendations is an average of ratings from different analysts but it should still be used with other research and investment metrics in order to make investment decisions. It is important to understand a firm's entire scale when assimilating ratings. Additionally, analyst recommendations on stocks owned by firms employing them may be seen as potentially biased.
Financial analysts are often employed by mutual and pension funds, hedge funds, securities firms, banks, investment banks, insurance companies, and other businesses, helping these companies or their clients make investment decisions. Financial analysts employed in commercial lending perform "balance sheet analysis," examining the audited financial statements and corollary data in order to assess lending risks. In a stock brokerage house or in an investment bank, they read company financial statements and analyze commodity prices, sales, costs, expenses, and tax rates in order to determine a company's value and project future earnings. In any of these various institutions, the analyst often meets with company officials to gain a better insight into a company's prospects and to determine the company's managerial effectiveness.
Usually, financial analysts study an entire industry, assessing current trends in business practices, products, and industry competition. They must keep abreast of new regulations or policies that may affect the industry, as well as monitor the economy to determine its effect on earnings.
Recommandation moyenne des entreprises dans Health Care secteur sur NASDAQ par rapport à Alimera Sciences
Que fait Alimera Sciences?
alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.
Entreprises avec recommandation moyenne similaire à Alimera Sciences
- Alimera Sciences a Recommandation moyenne de 1.00
- JOYY Inc a Recommandation moyenne de 1.05
- Honda Motor a Recommandation moyenne de 1.06
- Ares Capital Corp a Recommandation moyenne de 1.07
- Petroleo Brasileiro S.A. Petrobras a Recommandation moyenne de 1.08
- VNET Inc a Recommandation moyenne de 1.08
- Rocket Pharmaceuticals Inc a Recommandation moyenne de 1.08